Janet Dorling
Corporate Officer/Principal chez GILEAD SCIENCES, INC.
Profil
Janet Dorling is currently the Director at Gilead Sciences Belgium BV and the Senior VP- Intercontinental Region at Gilead Sciences, Inc. She previously worked as the Director at CymaBay Therapeutics, Inc. from 2021 to 2024, the VP-Breast Cancer Franchise & Global Product at Roche Holding AG from 2015 to 2017, the Chief Commercial Officer at CymaBay Therapeutics, Inc. in 2019, and the Chief Commercial Officer at Achaogen, Inc. from 2017 to 2019.
Ms. Dorling has a graduate degree from Duke University and an MBA from the University of California, Berkeley's Haas School of Business.
Postes actifs de Janet Dorling
| Sociétés | Poste | Début |
|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/05/2020 |
Gilead Sciences Belgium BV
 Gilead Sciences Belgium BV Medical DistributorsDistribution Services Gilead Sciences Belgium BV is a Belgian company that was founded in 2006. The private company is based in Machelen, Belgium. The company provides a portal for healthcare professionals under the name Gilead Sciences. | Director/Board Member | 01/02/2023 |
Anciens postes connus de Janet Dorling
| Sociétés | Poste | Fin |
|---|---|---|
| CYMABAY THERAPEUTICS, INC. | Director/Board Member | 22/03/2024 |
| CYMABAY THERAPEUTICS, INC. | Corporate Officer/Principal | 01/12/2019 |
| ACHAOGEN | Corporate Officer/Principal | 30/06/2019 |
| ROCHE HOLDING AG | Corporate Officer/Principal | 01/01/2017 |
Formation de Janet Dorling
| Duke University | Graduate Degree |
| University of California, Berkeley | Masters Business Admin |
| Haas School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| ROCHE HOLDING AG | Health Technology |
| Entreprise privées | 3 |
|---|---|
CymaBay Therapeutics, Inc.
 CymaBay Therapeutics, Inc. BiotechnologyHealth Technology CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA. | Health Technology |
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Gilead Sciences Belgium BV
Gilead Sciences Belgium BV Medical DistributorsDistribution Services Gilead Sciences Belgium BV is a Belgian company that was founded in 2006. The private company is based in Machelen, Belgium. The company provides a portal for healthcare professionals under the name Gilead Sciences. | Distribution Services |
